• 4-PBA: A Causal Tool for ER Stress Translation

  2026-09-04

  4-Phenylbutyric acid is more than an ER stress reagent: it is a strategic perturbation tool for testing whether proteostasis disruption drives ferroptosis, apoptosis, or autophagic cell death. This article connects mechanistic evidence from PFOS-exposed kidney cells with practical guidance for translational study design.

• Elobixibat hydrate: Applied Research Workflows

  2026-09-04

  Build gut-focused transport, secretion, motility, and metabolic assays around Elobixibat hydrate rather than treating it as a generic systemic drug. This workflow guide connects selective IBAT inhibition with exposure-aware sampling, practical controls, and troubleshooting for constipation, colonoscopy, and type 2 diabetes research.

• DHEA in PCOS Models: Reading the Mitochondrial Signal

  2026-09-03

  Dehydroepiandrosterone (DHEA) is more than a steroid precursor in PCOS research: it is a powerful model perturbation that exposes mitochondrial control of ovarian steroidogenesis. This article explains how to distinguish DHEA-induced phenotypes from treatment mechanisms and design assays around the StAR–cholesterol import checkpoint.

• Dasatinib Monohydrate: Reliable Cell Assays

  2026-09-03

  A scenario-based guide to using Dasatinib Monohydrate (SKU B5954) in cell viability, proliferation, and cytotoxicity workflows. It connects biochemical potency, solvent handling, CML models, NET-related interpretation, and practical product-selection criteria.

• Lopinavir: From HIV Protease to Assay Strategy

  2026-09-02

  Lopinavir (ABT-378) combines exceptional HIV protease potency with a valuable cell-based repurposing signal against MERS-CoV. This article develops an assay-centered framework for interpreting cross-pathogen activity without confusing phenotypic inhibition with validated coronavirus target engagement.

• Ertugliflozin (PF-04971729): Translational Strategy

  2026-09-02

  A mechanistic and translational roadmap for using PF-04971729 to connect renal glucose transport, cardiometabolic outcomes, and inflammation research.

• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-09-01

  This 2021 study identifies combined BRD4 and RAC1 inhibition as a subtype-aware strategy for limiting breast-cancer growth, migration, stem-like behavior, and xenograft tumorigenesis. Its mechanistic contribution is the connection of BRD4–RAC1 blockade to disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1, providing a framework for interpreting BET inhibitor responses beyond c-MYC suppression alone.

• Anlotinib Hydrochloride: An Assay-First Guide

  2026-09-01

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose value in cancer research depends on connecting receptor potency with endothelial phenotypes, ERK signaling, and disease-relevant models. This assay-first guide translates molecular data and a rare-tumor case report into practical experimental decisions.

• Anlotinib Hydrochloride: Angiogenesis Mechanism

  2026-08-31

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that blocks VEGFR2, PDGFRβ, and FGFR1 signaling. Peer-reviewed assays associate this anti-angiogenic small molecule with endothelial cell migration inhibition, capillary-like tube suppression, and ERK signaling pathway inhibition, supporting its use in cancer research.

• Tp47, PKM2, and Inflammatory Senescence

  2026-08-31

  The reference study identifies a mechanistic link between the Treponema pallidum protein Tp47, PKM2-dependent metabolic reprogramming, and inflammatory senescence in macrophages. Its findings connect pathogen-induced glycolytic changes with EIF2AK2 activation, NLRP3 inflammasome signaling, pyroptosis, and senescence-associated inflammatory output, providing a framework for interpreting senescent cell detection in infection models.

• Rocilinostat (ACY-1215): HDAC6 Research Guide

  2026-08-30

  Rocilinostat, also called ACY-1215, is a selective HDAC6 inhibitor with a reported biochemical IC50 of 5 nM. Preclinical multiple myeloma studies associate HDAC6 inhibition with increased α-tubulin acetylation, reduced tumor-cell viability, apoptosis, and enhanced proteasome-inhibitor activity.

• Tamsulosin: From Meta-Analysis to Assay Design

  2026-08-29

  Tamsulosin research is strongest when clinical effect sizes are translated into assay endpoints, stone-size strata, and exposure controls. This evidence-led guide connects α₁A pharmacology with reproducible ureteral, smooth-muscle, and translational study design.

• Venetoclax and Senescent Glioblastoma Cells After TMZ

  2026-08-28

  The reference study identifies a senescent cell anti-apoptotic program involving c-IAP2 and Bcl-2 after temozolomide exposure in glioblastoma models. Its key implication is that sequential inhibition with BV6 and venetoclax can selectively eliminate therapy-induced senescent cells, providing a framework for studying senolytic combinations rather than relying on additional DNA damage alone.

• Bromodomain Inhibitor, (+)-JQ1: Applied Workflows

  2026-08-28

  Bromodomain Inhibitor, (+)-JQ1 enables controlled BET chromatin perturbation across cancer, apoptosis, inflammation, and BRDT-focused reproductive biology. This practical guide connects mechanism to assay design, combination studies, storage, and troubleshooting for more reproducible results.

• Boc-D-FMK: A Mechanistic Guide to Caspase Control

  2026-08-27

  Boc-D-FMK is a cell-permeable pan-caspase inhibitor for dissecting apoptosis and inflammatory signaling. This guide connects its use in renal and hepatic models with a fibrosis study that clarifies how to distinguish pathway modulation from nonspecific loss of cell viability.

8124 records 1/542 page Next 12345 下5页 Last page